DMAC
HEALTHCAREDiaMedica Therapeutics Inc
$6.52+0.27 (+4.32%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DMAC Today?
No stock-specific AI insight has been generated for DMAC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.48$10.42
$6.52
Fundamentals
Market Cap$351M
P/E Ratio—
EPS$-0.70
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume185K
Avg Volume (10D)—
Shares Outstanding53.9M
DMAC News
20 articles- DiaMedica Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business HighlightsYahoo Finance·May 6, 2026
- DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026Yahoo Finance·Apr 30, 2026
- RedChip's Biotech Virtual Investor Conference Replays Now AvailableYahoo Finance·Apr 21, 2026
- DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip ConferenceMarketbeat·Apr 16, 2026
- RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare PlatformsYahoo Finance·Apr 7, 2026
- DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...Yahoo Finance·Mar 31, 2026
- DiaMedica Therapeutics Inc. Q4 2025 Earnings Call SummaryMoby·Mar 31, 2026
- DiaMedica Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
- DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business HighlightsYahoo Finance·Mar 30, 2026
- DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026Yahoo Finance·Mar 23, 2026
- DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in PreeclampsiaYahoo Finance·Mar 5, 2026
- Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsightYahoo Finance·Mar 2, 2026
- DiaMedica Therapeutics to Participate in Upcoming March Investor ConferencesYahoo Finance·Feb 24, 2026
- DiaMedica Therapeutics Insiders Added US$58.4m Of Stock To Their HoldingsYahoo Finance·Feb 15, 2026
- DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jan 16, 2026
- DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDAYahoo Finance·Dec 18, 2025
- Huge Insider Buying in MGM and Salesforce247 Wall St·Dec 12, 2025
- We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business GrowthYahoo Finance·Dec 1, 2025
- 3 Biotech Stocks Wall Street Analysts Predict Will More Than DoubleBarchart·Nov 20, 2025
All 20 articles loaded
Price Data
Open$6.04
Previous Close$6.25
Day High$6.26
Day Low$5.81
52 Week High$10.42
52 Week Low$3.48
52-Week Range
$3.48$10.42
$6.52
Fundamentals
Market Cap$351M
P/E Ratio—
EPS$-0.70
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume185K
Avg Volume (10D)—
Shares Outstanding53.9M
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—